Background: Drug eluting stents (DES) has been reported to reduce in-stent restenosis (ISR) in several randomized clinical trials. However, the differences in predictive factors of ISR following silorimus-eluting stent (SES) or parclitaxel-eluting stent (PES)implantation are currently unknown. Objective: This study investigated the differences of clinical, angiographic and procedural factors in predicting the risk of ISR associated with the current use of two types of DES. Methods: Since March 2003 to September 2004, 572 patients with de novo coronary artery disease were received SES(n=279) or PES(n=448). The patients (n=216, SES=59 patients, PES=157 patients) who were more than one year clinical follow-up and 9 months angiographic follow-up lesions (n=249, SES = 68 lesions, PES = 181 lesions) were analyzed for predictive factors of ISR. Results: There are no significant differences of patients and lesion characteristics in two groups. At 9 months angiograms, 5 SES patients (7.6%) and 22 PES patients (12.2%) had angiographic binary restenosis, respectively (p= 0.278). Diabetes mellitus (p=0.008) and 3-vessel disease(p=0.003) and long stent more than 25 mm (p=0.04) are independent multivariate predictors of ISR in both group. In the SES group, only 3-vessel disease (p=0.011) was the predictive factor of ISR. In PES group, diabetes mellitus (p=0.001), 3-vessel disease (p=0.011) and long stent length (p=0.035) are predictive factors. Conclusion: Diabetes mellitus, 3-vessel disease and long stent length were multivariate predictive factors for angiographic ISR after DES implantation. ISR was relatively less influenced by diabetes mellitus and long stents in SES group compared to PES group.